elotuzumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5072 915296-00-3

Description:

MoleculeDescription

Synonyms:

  • elotuzumab
  • empliciti
  • BMS-901608
  • HuLuc63
a humanized monoclonal antibody that selectively targets glycoproteins expressed on myeloma cells
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Sept. 28, 2016 PMDA Bristol-Myers Squibb
May 11, 2016 EMA Bristol-Myers Squibb
Nov. 30, 2015 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 197.19 25.38 86 2422 68038 50534578
Pneumonia 70.94 25.38 90 2418 378311 50224305
Plasma cell myeloma 69.62 25.38 33 2475 31289 50571327
Platelet count decreased 54.88 25.38 43 2465 100683 50501933
Pyrexia 53.81 25.38 79 2429 380124 50222492
Cytomegalovirus infection 52.78 25.38 23 2485 17939 50584677
Lymphocyte count decreased 47.31 25.38 24 2484 26283 50576333
Death 45.08 25.38 67 2441 325312 50277304
Neutrophil count decreased 37.24 25.38 25 2483 46001 50556615
Diarrhoea 32.50 25.38 82 2426 588394 50014222
Febrile neutropenia 31.54 25.38 31 2477 97636 50504980
Anaemia 30.67 25.38 49 2459 252407 50350209
Thrombocytopenia 29.65 25.38 34 2474 127639 50474977
Neuropathy peripheral 28.10 25.38 29 2479 96728 50505888

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 151.09 29.06 98 3313 73761 29497355
Pneumonia 101.98 29.06 152 3259 320020 29251096
Plasma cell myeloma 67.77 29.06 46 3365 37069 29534047
Platelet count decreased 42.29 29.06 56 3355 104616 29466500
Sepsis 38.35 29.06 63 3348 142619 29428497
Campylobacter gastroenteritis 37.66 29.06 10 3401 736 29570380
Febrile infection 35.65 29.06 12 3399 1992 29569124
Pneumonia respiratory syncytial viral 32.06 29.06 9 3402 815 29570301
Visceral leishmaniasis 31.28 29.06 8 3403 508 29570608
Squamous cell carcinoma of skin 30.77 29.06 17 3394 9469 29561647
Pneumonia mycoplasmal 30.36 29.06 8 3403 571 29570545
Neutropenia 29.90 29.06 54 3357 131657 29439459

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 307.33 26.94 157 4841 112714 64381020
Pneumonia 164.27 26.94 208 4790 559368 63934366
Platelet count decreased 93.88 26.94 88 4910 167623 64326111
Pyrexia 74.62 26.94 145 4853 558499 63935235
Plasma cell myeloma 70.24 26.94 44 4954 46031 64447703
Neutrophil count decreased 62.34 26.94 50 4948 77146 64416588
Sepsis 61.30 26.94 82 4916 230259 64263475
Lymphocyte count decreased 57.38 26.94 37 4961 40662 64453072
Anaemia 51.22 26.94 99 4899 378581 64115153
White blood cell count decreased 51.12 26.94 62 4936 157775 64335959
Neutropenia 50.01 26.94 76 4922 239548 64254186
Cytomegalovirus infection 47.99 26.94 32 4966 37167 64456567
Febrile neutropenia 47.13 26.94 65 4933 187592 64306142
Campylobacter gastroenteritis 37.60 26.94 10 4988 1106 64492628
Death 37.14 26.94 101 4897 482604 64011130
Febrile infection 35.97 26.94 12 4986 2889 64490845
Neuropathy peripheral 32.97 26.94 43 4955 117482 64376252
Atrial fibrillation 32.48 26.94 52 4946 171037 64322697
Thrombocytopenia 32.00 26.94 60 4938 223741 64269993
Septic shock 31.81 26.94 40 4958 105397 64388337
Squamous cell carcinoma of skin 30.63 26.94 16 4982 11860 64481874
Pulmonary embolism 27.10 26.94 44 4954 146312 64347422
Basal cell carcinoma 27.07 26.94 21 4977 30817 64462917

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
FDA CS M0001357 Antibodies, Monoclonal
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000192337 SLAMF7-directed Antibody Interactions
FDA EPC N0000192338 SLAMF7-directed Immunostimulatory Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Multiple myeloma indication 109989006 DOID:9538
Relapse multiple myeloma indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
SLAM family member 7 Membrane receptor ANTIBODY BINDING Kd 8.05 IUPHAR DRUG LABEL

External reference:

IDSource
1351PE5UGS UNII
4035187 VANDF
C1832049 UMLSCUI
CHEMBL1743010 ChEMBL_ID
DB06317 DRUGBANK_ID
9074 INN_ID
C546027 MESH_SUPPLEMENTAL_RECORD_UI
8361 IUPHAR_LIGAND_ID
1726104 RXNORM
237251 MMSL
31305 MMSL
d08403 MMSL
715660001 SNOMEDCT_US
781350003 SNOMEDCT_US
016608 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-2291 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 300 mg INTRAVENOUS BLA 26 sections
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-2291 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 300 mg INTRAVENOUS BLA 26 sections
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-4522 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 400 mg INTRAVENOUS BLA 26 sections
EMPLICITI HUMAN PRESCRIPTION DRUG LABEL 1 0003-4522 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 400 mg INTRAVENOUS BLA 26 sections